Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 8 years
- Director since
- 2023
8 years of board service in total across 3 boards, counting each seat separately. Longest: Altimmune Inc., 3 years.
Altimmune Inc.
Director
Jazz Pharmaceuticals plc
Director
Maze Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 7, 2026 | Maze Therapeutics Inc. | Option exercise | +20,744 | $10.42 | $216,152 |
| Jan 7, 2026 | Maze Therapeutics Inc. | Option exercise | +2,895 | $10.42 | $30,166 |
| Jan 7, 2026 | Maze Therapeutics Inc. | Option exercise | +3,281 | $10.42 | $34,188 |
| Jan 7, 2026 | Maze Therapeutics Inc. | Open-market sale | −26,920 | $39.11 | $1,052,841 |
| Jan 6, 2026 | Maze Therapeutics Inc. | Option exercise | +2,493 | $10.42 | $25,977 |
| Jan 6, 2026 | Maze Therapeutics Inc. | Open-market sale | −2,493 | $38.62 | $96,280 |
| Jan 5, 2026 | Altimmune Inc. | Open-market purchase | +500 | $4.24 | $2,120 |
| Mar 17, 2025 | Altimmune Inc. | Open-market purchase | +1,000 | $5.78 | $5,780 |
| Aug 14, 2023 | Jazz Pharmaceuticals plc | Open-market sale | −1,241 | $138.16 | $171,457 |
| Aug 11, 2023 | Jazz Pharmaceuticals plc | Grant or award | +3,075 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.